Prostate Cancer

Prostate Cancer
2024-12-02T06:32:48.071Z

ProstACT-Global-203

ProstACT-Global-203
Prostate cancer

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177 Lu) rosopatamab tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously after Androgen Receptor Pathway Inhibitor Treatment

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177 Lu) rosopatamab tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously after Androgen Receptor Pathway Inhibitor Treatment

Trial overview

Clinical Area

Theranostics

Disease / Condition

Prostate cancer

Study Phase

III

Trial Identifiers
GenesisCare Location(s)
Murdoch (Oncology)
location pin icon

St John of God Murdoch Hospital, 100 Murdoch Drive, Murdoch, WA, 6150, Australia

phone icon (08) 9366 1500 email icon receptiononcologymurdoch@genesiscare.com
WA
Murdoch (Oncology)
Principal Investigator(s)
Nuclear Medicine Physician

Dr Aviral Singh

MD PGDipCard MSc FAfNM FRACP - Clinical Head of Theranostics and Nuclear Medicine

Dr Aviral Singh
location pin icon

Murdoch (Oncology)

View Profile
Profile Image - Dr Aviral Singh

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.